Live Earnings Conference Call: ACADIA Pharmaceuticals' Q1 2026 earnings call is happening now. Listen live.

ACADIA Pharmaceuticals (ACAD) Financials

$21.48 -0.87 (-3.89%)

Closing price 04:00 PM Eastern

Extended Trading

$21.30 -0.18 (-0.83%)

As of 04:31 PM Eastern

Compare

Annual Income Statements for ACADIA Pharmaceuticals

This table shows ACADIA Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-164	-271	-289	-245	-235	-282	-168	-216	-61	226	391
Consolidated Net Income / (Loss)	-164	-271	-289	-245	-235	-282	-168	-216	-61	226	391
Net Income / (Loss) Continuing Operations	-164	-271	-289	-245	-235	-282	-168	-216	-61	226	391
Total Pre-Tax Income	-164	-270	-288	-244	-234	-281	-168	-213	-51	258	139
Total Operating Income	-165	-273	-292	-247	-247	-287	-170	-224	-73	231	105
Total Gross Profit	0.06	14	116	211	328	432	465	507	685	876	983
Total Revenue	0.06	17	125	224	339	442	484	517	726	958	1,072
Operating Revenue	0.00	17	125	224	339	442	484	517	726	958	1,072
Total Cost of Revenue	0.00	3.08	9.08	12	11	10	19	10	42	82	89
Operating Cost of Revenue	-	3.08	9.08	12	11	10	19	10	42	82	89
Total Operating Expenses	165	287	408	459	574	718	635	731	758	645	878
Selling, General & Admin Expense	88	186	255	266	326	389	396	369	407	488	549
Research & Development Expense	74	99	149	187	240	319	239	362	352	303	329
Other Special Charges / (Income)	-	-	-	-	-	-	-	-	0.00	-147	0.00
Total Other Income / (Expense), net	0.50	2.76	4.13	3.51	12	5.61	2.92	10	22	27	34
Interest & Investment Income	0.50	2.76	4.13	5.35	11	6.61	0.59	6.61	17	25	32
Other Income / (Expense), net	-	0.00	0.00	-1.84	1.00	-1.00	2.33	3.54	5.11	1.82	2.37
Income Tax Expense	0.33	1.34	1.12	1.26	0.88	0.61	0.35	2.53	10	32	-252
Basic Earnings per Share	($1.63)	($2.34)	($2.36)	($1.94)	($1.60)	($1.79)	($1.05)	($1.34)	($0.37)	$1.37	$2.32
Weighted Average Basic Shares Outstanding	100.63M	115.86M	122.60M	126.58M	147.20M	157.33M	160.49M	161.68M	163.82M	165.72M	168.36M
Diluted Earnings per Share	($1.63)	($2.34)	($2.36)	($1.94)	($1.60)	($1.79)	($1.05)	($1.34)	($0.37)	$1.36	$2.30
Weighted Average Diluted Shares Outstanding	100.63M	115.86M	122.60M	126.58M	147.20M	157.33M	160.49M	161.68M	163.82M	166.36M	169.92M
Weighted Average Basic & Diluted Shares Outstanding	100.63M	115.86M	122.60M	126.58M	147.20M	157.33M	160.49M	162.23M	164.77M	166.79M	170.49M

This table shows ACADIA Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	1.11	-65	46	17	33	33	144	19	27	72	274
Consolidated Net Income / (Loss)	1.11	-65	46	17	33	33	144	19	27	72	274
Net Income / (Loss) Continuing Operations	1.11	-65	46	17	33	33	146	19	27	72	274
Total Pre-Tax Income	6.34	-52	40	21	37	39	161	28	40	45	26
Total Operating Income	3.04	-58	35	15	30	32	154	19	32	36	17
Total Gross Profit	158	197	213	183	224	232	238	224	244	257	258
Total Revenue	165	212	231	206	242	250	260	244	265	279	284
Operating Revenue	165	212	231	206	242	250	260	244	265	279	284
Total Cost of Revenue	7.46	15	18	23	18	19	22	20	21	22	26
Operating Cost of Revenue	7.46	15	18	23	18	19	22	20	21	22	26
Total Operating Expenses	155	255	178	168	193	200	84	205	211	221	240
Selling, General & Admin Expense	96	98	111	108	117	133	130	126	134	133	156
Research & Development Expense	59	157	67	60	76	67	101	78	78	88	85
Total Other Income / (Expense), net	3.31	5.63	4.76	5.79	6.75	7.16	5.76	8.49	7.84	8.84	8.93
Interest & Investment Income	4.55	4.13	4.76	5.51	6.36	6.59	7.01	7.90	7.24	8.25	8.33
Other Income / (Expense), net	-1.24	1.51	-	0.29	0.39	0.58	-	0.59	0.59	0.59	0.60
Income Tax Expense	5.23	13	-6.09	4.45	3.79	6.04	17	8.79	14	-27	-247
Basic Earnings per Share	$0.01	($0.40)	$0.29	$0.10	$0.20	$0.20	$0.87	$0.11	$0.16	$0.43	$1.62
Weighted Average Basic Shares Outstanding	163.46M	164.23M	163.82M	164.80M	165.55M	165.97M	165.72M	166.81M	167.83M	168.84M	168.36M
Diluted Earnings per Share	$0.01	($0.40)	$0.29	$0.10	$0.20	$0.20	$0.86	$0.11	$0.16	$0.42	$1.61
Weighted Average Diluted Shares Outstanding	165.05M	164.23M	163.82M	166.62M	166.17M	166.18M	166.36M	167.67M	168.68M	170.65M	169.92M
Weighted Average Basic & Diluted Shares Outstanding	163.73M	164.18M	164.77M	165.22M	165.88M	166.39M	166.79M	167.36M	168.71M	169.18M	170.49M

This table details how cash moves in and out of ACADIA Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	40	63	-94	68	55	137	-179	-33	74	134	-143
Net Cash From Operating Activities	-122	-208	-218	-167	-151	-136	-126	-114	17	158	110
Net Cash From Continuing Operating Activities	-122	-208	-218	-167	-151	-136	-126	-114	17	158	110
Net Income / (Loss) Continuing Operations	-164	-271	-289	-245	-235	-282	-168	-216	-61	226	391
Consolidated Net Income / (Loss)	-164	-271	-289	-245	-235	-282	-168	-216	-61	226	391
Depreciation Expense	0.65	0.84	1.24	1.53	1.29	1.46	2.24	2.03	1.46	0.92	0.87
Amortization Expense	-2.06	1.07	1.19	0.90	-2.14	2.95	3.51	-2.74	-3.44	5.66	5.47
Non-Cash Adjustments To Reconcile Net Income	40	55	76	83	85	134	68	71	68	-72	61
Changes in Operating Assets and Liabilities, net	4.11	6.39	-6.31	-8.20	-0.17	6.76	-31	31	12	-3.35	-348
Net Cash From Investing Activities	148	-262	92	-71	-166	193	-71	73	32	-31	-303
Net Cash From Continuing Investing Activities	148	-262	92	-71	-166	193	-71	73	32	-31	-303
Purchase of Property, Plant & Equipment	-2.14	-1.51	-0.81	-2.10	-1.13	-7.59	-1.12	0.00	-0.05	-0.52	-4.69
Acquisitions	0.00	-8.00	-	-	-	-	0.00	0.00	-40	0.00	-99
Purchase of Investments	-269	-683	-479	-331	-579	-340	-493	-363	-370	-505	-693
Sale and/or Maturity of Investments	419	431	572	262	414	540	423	436	442	329	494
Other Investing Activities, net	-	-	-	-	-	-	-	0.00	0.00	147	0.00
Net Cash From Financing Activities	15	534	31	307	372	81	18	8.20	25	6.85	50
Net Cash From Continuing Financing Activities	15	534	31	307	372	81	18	8.20	25	6.85	50
Issuance of Common Equity	15	519	31	307	372	81	18	8.20	25	6.85	50
Effect of Exchange Rate Changes	0.01	0.00	-0.01	0.00	0.00	-0.01	0.01	0.01	-0.02	-0.09	0.03
Cash Income Taxes Paid	0.42	-0.37	1.37	1.26	1.60	1.11	1.04	2.19	5.85	20	25

This table details how cash moves in and out of ACADIA Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-181	-12	90	16	-28	-19	164	-102	37	4.36	-82
Net Cash From Operating Activities	8.20	-59	85	29	25	63	40	20	64	74	-49
Net Cash From Continuing Operating Activities	8.20	-59	85	29	25	63	40	20	64	74	-49
Net Income / (Loss) Continuing Operations	1.11	-65	46	17	33	33	144	19	27	72	274
Consolidated Net Income / (Loss)	1.11	-65	46	17	33	33	144	19	27	72	274
Depreciation Expense	0.40	0.36	0.27	0.24	0.23	0.23	0.23	0.23	0.21	0.23	0.20
Amortization Expense	-0.13	-0.63	-0.41	3.50	0.39	-0.40	2.17	0.61	1.19	1.62	2.05
Non-Cash Adjustments To Reconcile Net Income	18	19	19	17	18	28	-134	14	16	15	15
Changes in Operating Assets and Liabilities, net	-11	-12	21	-7.73	-27	3.02	28	-13	19	-15	-340
Net Cash From Investing Activities	-194	34	-0.35	-14	-56	-82	122	-124	-43	-79	-56
Net Cash From Continuing Investing Activities	-194	34	-0.35	-14	-56	-82	122	-124	-43	-79	-56
Purchase of Property, Plant & Equipment	-	-	-	0.00	-	-	-0.45	0.00	-0.30	-0.39	-4.01
Purchase of Investments	-162	-37	-104	-80	-138	-151	-136	-156	-174	-205	-158
Sale and/or Maturity of Investments	7.50	71	104	66	82	69	112	131	131	126	106
Net Cash From Financing Activities	5.48	13	5.43	1.04	3.57	0.27	1.97	1.84	16	9.42	23
Net Cash From Continuing Financing Activities	5.48	13	5.43	1.04	3.57	0.27	1.97	1.84	16	9.42	23
Issuance of Common Equity	5.48	13	5.43	1.04	3.57	0.27	1.97	1.84	16	9.42	23
Effect of Exchange Rate Changes	-	-0.00	-0.01	0.01	0.00	-0.04	-0.06	-0.01	0.02	-	0.01

This table presents ACADIA Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	222	561	385	540	783	783	700	588	749	1,188	1,564
Total Current Assets	219	548	373	526	760	718	618	508	616	938	1,062
Cash & Equivalents	102	164	69	135	190	326	147	115	189	320	178
Restricted Cash	0.38	2.38	-	4.83	4.79	5.77	-	-	5.77	8.77	7.85
Short-Term Investments	113	365	272	339	508	306	373	302	250	436	642
Note & Lease Receivable	1.64	1.24	1.09	1.70	2.09	2.04	0.98	0.89	4.08	5.96	27
Accounts Receivable	0.00	5.90	17	26	36	48	64	62	98	99	121
Inventories, net	0.00	4.18	5.25	4.07	6.34	9.68	7.88	6.64	36	22	35
Prepaid Expenses	2.22	7.55	8.46	21	19	26	24	21	39	56	60
Plant, Property, & Equipment, net	2.20	3.08	2.66	3.31	3.18	9.16	8.05	6.02	4.61	4.22	7.51
Total Noncurrent Assets	0.33	7.80	8.37	5.96	15	50	74	74	122	236	487
Intangible Assets	0.00	7.02	5.54	4.06	2.59	1.11	0.00	0.00	65	120	109
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	-	0.00	250
Other Noncurrent Operating Assets	0.33	0.79	2.83	1.90	12	49	74	74	57	117	128
Total Liabilities & Shareholders' Equity	222	561	385	540	783	783	700	588	749	1,188	1,564
Total Liabilities	22	43	49	61	84	156	159	187	317	455	337
Total Current Liabilities	22	43	49	60	75	106	96	126	254	395	277
Accounts Payable	1.67	3.91	8.79	3.17	7.22	8.49	6.88	13	18	16	11
Accrued Expenses	20	36	40	56	68	97	89	113	237	379	266
Total Noncurrent Liabilities	0.23	0.16	0.19	1.56	9.22	50	63	62	63	60	60
Capital Lease Obligations	-	-	-	0.00	6.36	44	-	-	48	42	41
Other Noncurrent Operating Liabilities	-	-	-	1.56	2.86	5.18	63	62	15	18	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	200	518	335	479	699	627	541	400	432	733	1,227
Total Preferred & Common Equity	200	518	335	479	699	627	541	400	432	733	1,227
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	200	518	335	479	699	627	541	400	432	733	1,227
Common Stock	862	1,452	1,559	1,948	2,403	2,613	2,695	2,771	2,863	2,937	3,039
Retained Earnings	-663	-934	-1,224	-1,469	-1,704	-1,986	-2,154	-2,370	-2,431	-2,204	-1,813
Accumulated Other Comprehensive Income / (Loss)	0.01	0.11	-0.40	-0.37	0.30	0.04	-0.19	-0.98	0.02	0.29	1.45

This table presents ACADIA Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	602	655	643	633	855	914	977	1,132	1,226	1,331
Total Current Assets	522	503	493	499	675	729	788	871	961	1,076
Cash & Equivalents	155	291	108	98	205	177	155	218	254	258
Restricted Cash	-	-	-	-	5.77	5.77	-	-	9.47	9.47
Short-Term Investments	282	112	267	248	266	324	410	464	508	589
Note & Lease Receivable	0.40	4.34	2.30	1.73	5.38	6.70	12	7.97	12	24
Accounts Receivable	56	66	82	93	95	104	98	106	108	116
Inventories, net	5.84	6.10	9.20	21	62	72	61	23	26	29
Prepaid Expenses	23	24	24	38	43	46	52	53	53	61
Plant, Property, & Equipment, net	6.51	5.60	5.19	4.88	4.37	4.14	3.99	3.50	3.55	3.71
Total Noncurrent Assets	74	147	145	128	170	175	185	258	252	241
Intangible Assets	-	70	68	67	110	108	106	117	114	112
Other Noncurrent Operating Assets	74	77	77	62	59	67	79	141	138	130
Total Liabilities & Shareholders' Equity	602	655	643	633	855	914	977	1,132	1,226	1,331
Total Liabilities	177	281	247	270	391	397	400	367	403	413
Total Current Liabilities	117	224	188	210	331	338	344	303	330	357
Accounts Payable	10	17	19	12	19	20	19	18	20	22
Accrued Expenses	107	207	169	197	311	318	325	284	310	335
Total Noncurrent Liabilities	60	57	59	61	60	60	56	65	73	57
Capital Lease Obligations	-	-	-	-	49	47	-	-	45	43
Other Noncurrent Operating Liabilities	60	57	59	61	11	12	56	65	29	14
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	426	374	396	362	464	517	577	765	822	917
Total Preferred & Common Equity	426	374	396	362	464	517	577	765	822	917
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	426	374	396	362	464	517	577	765	822	917
Common Stock	2,755	2,787	2,808	2,839	2,879	2,898	2,924	2,950	2,981	3,003
Retained Earnings	-2,328	-2,413	-2,411	-2,477	-2,414	-2,381	-2,348	-2,185	-2,159	-2,087
Accumulated Other Comprehensive Income / (Loss)	-1.37	-0.22	-0.54	-0.32	-0.23	-0.34	0.86	0.44	0.41	0.99

This table displays calculated financial ratios and metrics derived from ACADIA Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-49.17%	28,311.48%	620.68%	79.19%	51.50%	30.28%	9.60%	6.83%	40.45%	31.85%	11.87%
EBITDA Growth	-79.41%	-63.17%	-7.05%	14.87%	0.19%	-14.93%	42.66%	-35.97%	68.18%	437.89%	-52.54%
EBIT Growth	-76.57%	-65.73%	-7.18%	14.75%	1.50%	-17.12%	41.54%	-30.90%	68.98%	438.06%	-53.92%
NOPAT Growth	-76.57%	-65.73%	-7.18%	15.38%	0.36%	-16.24%	40.53%	-31.19%	67.18%	494.26%	45.69%
Net Income Growth	-77.82%	-65.04%	-6.64%	15.28%	4.05%	-19.69%	40.38%	-28.66%	71.62%	469.50%	72.66%
EPS Growth	-71.58%	-43.56%	-0.85%	17.80%	17.53%	-11.88%	41.34%	-27.62%	72.39%	467.57%	69.12%
Operating Cash Flow Growth	-83.33%	-71.11%	-4.49%	23.09%	9.76%	9.90%	7.72%	9.25%	114.65%	844.31%	-30.36%
Free Cash Flow Firm Growth	-100.85%	-72.01%	-9.31%	15.05%	2.60%	-31.94%	54.23%	-13.39%	14.36%	321.40%	-159.51%
Invested Capital Growth	-20.61%	17.21%	54.33%	112.50%	347.48%	928.69%	-40.17%	-181.29%	312.80%	-71.17%	4,274.82%
Revenue Q/Q Growth	-32.97%	221.78%	33.87%	7.70%	12.90%	5.41%	2.06%	1.12%	14.96%	3.07%	2.33%
EBITDA Q/Q Growth	-11.59%	-13.42%	2.75%	0.39%	4.40%	-3.79%	12.80%	-2.11%	53.53%	101.98%	-54.12%
EBIT Q/Q Growth	-11.52%	-13.60%	2.73%	0.36%	4.61%	-4.26%	12.56%	-0.81%	53.79%	103.37%	-55.51%
NOPAT Q/Q Growth	-11.52%	-13.60%	2.73%	1.09%	4.23%	-3.90%	11.66%	-0.63%	52.47%	91.93%	28.32%
Net Income Q/Q Growth	-11.85%	-13.80%	3.28%	1.36%	5.03%	-5.12%	12.36%	0.63%	58.82%	76.22%	49.71%
EPS Q/Q Growth	-10.88%	-9.35%	3.67%	3.48%	8.57%	-4.07%	11.76%	0.74%	59.78%	72.15%	48.39%
Operating Cash Flow Q/Q Growth	-16.13%	-14.55%	12.57%	-5.80%	5.84%	1.60%	3.36%	-0.65%	118.05%	-22.20%	-44.79%
Free Cash Flow Firm Q/Q Growth	-15.46%	-15.12%	8.73%	-1.49%	0.90%	2.11%	35.37%	-81.51%	24.05%	106.85%	-198.08%
Invested Capital Q/Q Growth	-18.37%	1.20%	-169.25%	-93.03%	-53.37%	-32.52%	-74.31%	-50.65%	114.84%	-15.05%	324.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	82.26%	92.73%	94.47%	96.65%	97.69%	96.05%	98.03%	94.27%	91.46%	91.69%
EBITDA Margin	-272,172.13%	-1,563.08%	-232.17%	-110.30%	-72.67%	-64.10%	-33.54%	-42.68%	-9.67%	24.78%	10.59%
Operating Margin	-269,855.74%	-1,574.14%	-234.11%	-110.56%	-72.71%	-64.87%	-35.20%	-43.23%	-10.10%	24.10%	9.78%
EBIT Margin	-269,855.74%	-1,574.14%	-234.11%	-111.38%	-72.42%	-65.10%	-34.72%	-42.54%	-9.40%	24.10%	10.00%
Profit (Net Income) Margin	-269,578.69%	-1,565.94%	-231.71%	-109.56%	-69.38%	-63.74%	-34.67%	-41.76%	-8.44%	23.64%	36.49%
Tax Burden Percent	100.20%	100.50%	100.39%	100.51%	100.37%	100.22%	100.21%	101.19%	120.08%	87.75%	281.49%
Interest Burden Percent	99.70%	98.99%	98.59%	97.85%	95.45%	97.70%	99.65%	97.00%	74.76%	111.82%	129.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12.25%	-181.49%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-8,601.12%	-1,083.76%	-442.46%	-8,285.72%	-555.00%	900.32%	130.99%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-8,590.45%	-1,071.20%	-433.74%	-8,273.03%	-552.56%	896.04%	118.27%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	8,561.19%	1,041.30%	413.71%	8,239.83%	540.27%	-861.43%	-91.09%
Return on Equity (ROE)	-64.58%	-75.58%	-67.80%	-60.22%	-39.93%	-42.47%	-28.75%	-45.89%	-14.73%	38.89%	39.89%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-24,530.67%	-8,728.06%	-1,248.33%	-392.20%	0.00%	-294.09%	1,010.81%	-60.08%
Operating Return on Assets (OROA)	-60.15%	-69.68%	-61.84%	-53.92%	-37.11%	-36.73%	-22.68%	-34.17%	-10.21%	23.83%	7.79%
Return on Assets (ROA)	-60.09%	-69.32%	-61.21%	-53.03%	-35.55%	-35.97%	-22.64%	-33.54%	-9.17%	23.39%	28.42%
Return on Common Equity (ROCE)	-64.58%	-75.58%	-67.80%	-60.22%	-39.93%	-42.47%	-28.75%	-45.89%	-14.73%	38.89%	39.89%
Return on Equity Simple (ROE_SIMPLE)	-82.32%	-52.35%	-86.32%	-51.18%	-33.65%	-44.91%	-31.04%	-53.94%	-14.19%	30.90%	0.00%
Net Operating Profit after Tax (NOPAT)	-115	-191	-205	-173	-173	-201	-119	-157	-51	203	295
NOPAT Margin	-188,899.02%	-1,101.90%	-163.88%	-77.39%	-50.90%	-45.41%	-24.64%	-30.26%	-7.07%	21.14%	27.53%
Net Nonoperating Expense Percent (NNEP)	-18.31%	-21.55%	-19.42%	-17.57%	-10.68%	-12.56%	-8.72%	-12.68%	-2.44%	4.28%	12.71%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-39.09%	-10.71%	26.14%	23.27%
Cost of Revenue to Revenue	0.00%	17.74%	7.27%	5.53%	3.35%	2.31%	3.95%	1.97%	5.73%	8.54%	8.31%
SG&A Expenses to Revenue	144,760.66%	1,075.85%	204.21%	118.74%	96.04%	87.98%	81.80%	71.36%	55.97%	50.99%	51.23%
R&D to Revenue	121,096.72%	572.87%	119.45%	83.63%	70.89%	72.24%	49.45%	69.91%	48.40%	31.66%	30.69%
Operating Expenses to Revenue	269,955.74%	1,656.40%	326.85%	205.03%	169.37%	162.56%	131.25%	141.26%	104.37%	67.36%	81.91%
Earnings before Interest and Taxes (EBIT)	-165	-273	-292	-249	-246	-288	-168	-220	-68	231	107
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-166	-271	-290	-247	-246	-283	-162	-221	-70	237	114
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	18.01	6.74	11.15	4.22	9.42	13.55	6.94	6.44	11.91	4.17	3.68
Price to Tangible Book Value (P/TBV)	18.01	6.83	11.34	4.26	9.46	13.58	6.94	6.44	14.03	4.98	4.04
Price to Revenue (P/Rev)	58,975.40	201.54	29.94	9.04	19.43	19.24	7.75	4.98	7.08	3.19	4.22
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.48	11.56
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	7.42%	8.65%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	2,106.56	1,796.75	234.31	160.06	0.00	135.84	231.51	8.47
Enterprise Value to Revenue (EV/Rev)	55,442.50	170.88	27.21	6.90	17.38	17.90	6.67	4.18	6.53	2.43	3.48
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.82	32.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.10	34.82
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.51	12.65
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	284.02	14.78	33.98
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.25	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.07	0.00	0.00	0.11	0.06	0.03
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.07	0.00	0.00	0.11	0.06	0.03
Financial Leverage	-1.06	-1.04	-1.02	-1.01	-1.00	-0.97	-0.95	-1.00	-0.98	-0.96	-0.77
Leverage Ratio	1.07	1.09	1.11	1.14	1.12	1.18	1.27	1.37	1.61	1.66	1.40
Compound Leverage Factor	1.07	1.08	1.09	1.11	1.07	1.15	1.27	1.33	1.20	1.86	1.82
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.90%	6.62%	0.00%	0.00%	9.97%	5.43%	3.20%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.90%	6.62%	0.00%	0.00%	9.97%	5.43%	3.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	99.10%	93.38%	100.00%	100.00%	90.03%	94.57%	96.80%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.03	-0.16	0.00	0.00	-0.68	0.18	0.36
Net Debt to EBITDA	0.00	0.00	0.00	0.00	2.82	2.10	0.00	0.00	5.65	-3.04	-6.93
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.03	-0.16	0.00	0.00	-0.68	0.18	0.36
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.04	-0.22	0.00	0.00	-0.93	0.21	0.14
Net Debt to NOPAT	0.00	0.00	0.00	0.00	4.03	2.96	0.00	0.00	7.73	-3.57	-2.67
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.04	-0.22	0.00	0.00	-0.93	0.21	0.14
Altman Z-Score	91.96	46.21	39.96	15.97	44.44	29.51	10.63	3.04	6.43	3.43	7.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.00	12.87	7.62	8.83	10.16	6.77	6.43	4.04	2.42	2.38	3.83
Quick Ratio	9.90	12.59	7.34	8.42	9.83	6.44	6.10	3.82	2.13	2.18	3.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-113	-194	-212	-180	-175	-231	-106	-120	-103	227	-135
Operating Cash Flow to CapEx	-5,688.70%	-13,838.51%	-26,817.36%	-7,959.60%	-13,386.18%	-1,794.73%	-11,199.64%	0.00%	33,404.00%	30,156.60%	2,341.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.04	0.26	0.48	0.51	0.56	0.65	0.80	1.09	0.99	0.78
Accounts Receivable Turnover	0.00	0.00	10.75	10.31	10.96	10.51	8.60	8.17	9.05	9.72	9.73
Inventory Turnover	0.00	0.00	1.93	2.66	2.18	1.27	2.18	1.40	1.96	2.83	3.14
Fixed Asset Turnover	0.04	6.56	43.50	74.96	104.51	71.59	56.27	73.53	136.64	217.02	182.76
Accounts Payable Turnover	0.00	1.10	1.43	2.07	2.18	1.30	2.49	1.04	2.75	4.85	6.57
Days Sales Outstanding (DSO)	0.00	0.00	33.97	35.42	33.30	34.71	42.45	44.66	40.31	37.54	37.50
Days Inventory Outstanding (DIO)	0.00	0.00	189.46	137.39	167.49	286.38	167.45	260.61	186.08	128.82	116.10
Days Payable Outstanding (DPO)	0.00	331.41	255.30	176.25	167.14	280.87	146.54	352.25	132.76	75.23	55.56
Cash Conversion Cycle (CCC)	0.00	-331.41	-31.88	-3.44	33.65	40.22	63.37	-46.99	93.64	91.13	98.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-16	-13	-5.87	0.73	3.28	34	20	-16	35	10	440
Invested Capital Turnover	0.00	-1.22	-13.35	-87.20	168.99	23.87	17.95	273.81	78.49	42.58	4.76
Increase / (Decrease) in Invested Capital	-2.65	2.67	6.98	6.60	2.55	30	-14	-37	51	-25	430
Enterprise Value (EV)	3,382	2,962	3,398	1,544	5,893	7,906	3,231	2,161	4,744	2,331	3,732
Market Capitalization	3,597	3,493	3,740	2,022	6,589	8,499	3,752	2,578	5,140	3,053	4,519
Book Value per Share	$1.98	$4.28	$2.70	$3.83	$4.54	$3.94	$3.36	$2.47	$2.63	$4.40	$7.25
Tangible Book Value per Share	$1.98	$4.22	$2.65	$3.80	$4.52	$3.94	$3.36	$2.47	$2.23	$3.68	$6.61
Total Capital	200	518	335	479	705	671	541	400	480	775	1,268
Total Debt	0.00	0.00	0.00	0.00	6.36	44	0.00	0.00	48	42	41
Total Long-Term Debt	0.00	0.00	0.00	0.00	6.36	44	0.00	0.00	48	42	41
Net Debt	-216	-531	-341	-478	-696	-593	-521	-417	-397	-723	-787
Capital Expenditures (CapEx)	2.14	1.51	0.81	2.10	1.13	7.59	1.12	0.00	0.05	0.52	4.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-26	-17	-12	-17	-26	1.05	-35	-83	-221	-43
Debt-free Net Working Capital (DFNWC)	197	505	324	467	685	612	522	382	362	543	785
Net Working Capital (NWC)	197	505	324	467	685	612	522	382	362	543	785
Net Nonoperating Expense (NNE)	49	80	85	72	63	81	49	59	9.92	-24	-96
Net Nonoperating Obligations (NNO)	-215	-531	-341	-478	-696	-593	-521	-417	-397	-723	-787
Total Depreciation and Amortization (D&A)	-1.41	1.92	2.42	2.43	-0.85	4.40	5.75	-0.71	-1.98	6.58	6.34
Debt-free, Cash-free Net Working Capital to Revenue	-30,196.72%	-150.59%	-13.53%	-5.27%	-4.95%	-5.90%	0.22%	-6.67%	-11.39%	-23.11%	-3.97%
Debt-free Net Working Capital to Revenue	323,093.44%	2,915.65%	259.76%	208.46%	202.14%	138.46%	107.77%	73.91%	49.81%	56.74%	73.26%
Net Working Capital to Revenue	323,093.44%	2,915.65%	259.76%	208.46%	202.14%	138.46%	107.77%	73.91%	49.81%	56.74%	73.26%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.63)	($2.34)	($2.36)	($1.94)	($1.60)	($1.79)	($1.05)	($1.34)	($0.37)	$1.37	$2.32
Adjusted Weighted Average Basic Shares Outstanding	112.64M	121.41M	124.70M	143.88M	155.34M	160.05M	161.20M	161.68M	163.82M	165.72M	168.36M
Adjusted Diluted Earnings per Share	($1.63)	($2.34)	($2.36)	($1.94)	($1.60)	($1.79)	($1.05)	($1.34)	($0.37)	$1.36	$2.30
Adjusted Weighted Average Diluted Shares Outstanding	112.64M	121.41M	124.70M	143.88M	155.34M	160.05M	161.20M	161.68M	163.82M	166.36M	169.92M
Adjusted Basic & Diluted Earnings per Share	($1.63)	($2.34)	($2.36)	($1.94)	($1.60)	($1.79)	($1.05)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	100.63M	115.86M	122.60M	126.58M	147.20M	157.33M	160.49M	162.23M	164.77M	166.79M	170.49M
Normalized Net Operating Profit after Tax (NOPAT)	-115	-191	-205	-173	-173	-201	-119	-157	-51	74	73
Normalized NOPAT Margin	-188,899.02%	-1,101.90%	-163.88%	-77.39%	-50.90%	-45.41%	-24.64%	-30.26%	-7.07%	7.72%	6.85%
Pre Tax Income Margin	-269,037.70%	-1,558.20%	-230.81%	-108.99%	-69.12%	-63.60%	-34.60%	-41.27%	-7.03%	26.94%	12.96%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.18%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ACADIA Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.79%	61.96%	69.27%	73.75%	46.44%	18.28%	12.36%	18.70%	9.34%	11.27%	9.39%
EBITDA Growth	106.17%	-92.36%	175.45%	138.03%	1,420.31%	156.67%	347.96%	7.67%	9.31%	19.21%	-87.06%
EBIT Growth	105.25%	-95.99%	178.49%	131.79%	1,619.07%	157.26%	339.28%	28.28%	6.96%	12.82%	-88.33%
NOPAT Growth	102.26%	-87.18%	225.01%	131.96%	5,024.33%	166.06%	239.83%	9.97%	-21.45%	115.41%	31.97%
Net Income Growth	103.28%	-139.77%	209.76%	138.48%	2,897.22%	150.27%	213.87%	14.69%	-20.14%	119.07%	90.32%
EPS Growth	104.76%	-135.29%	211.54%	137.04%	1,900.00%	150.00%	196.55%	10.00%	-20.00%	110.00%	87.21%
Operating Cash Flow Growth	162.48%	-8,009.35%	457.97%	262.15%	205.00%	207.28%	-52.71%	-30.11%	155.69%	17.46%	-220.68%
Free Cash Flow Firm Growth	-154.51%	-199.61%	-353.16%	-431.76%	55.92%	146.05%	1,568.18%	37.40%	-78.99%	-210.55%	-254.22%
Invested Capital Growth	1,458.28%	249.22%	312.80%	229.10%	180.06%	-27.09%	-71.17%	126.46%	67.06%	776.02%	4,274.82%
Revenue Q/Q Growth	39.48%	28.12%	9.14%	-10.91%	17.55%	3.49%	3.67%	-5.89%	8.29%	5.32%	1.92%
EBITDA Q/Q Growth	104.09%	-2,834.09%	161.55%	-44.72%	63.43%	1.92%	386.53%	-86.71%	65.92%	11.14%	-47.01%
EBIT Q/Q Growth	103.68%	-3,238.20%	162.10%	-55.65%	98.91%	4.53%	376.42%	-87.05%	65.85%	10.26%	-50.52%
NOPAT Q/Q Growth	101.42%	-7,682.46%	199.66%	-70.26%	127.97%	-2.25%	412.68%	-90.37%	62.83%	168.07%	214.09%
Net Income Q/Q Growth	102.59%	-5,950.63%	170.27%	-63.85%	101.69%	-1.87%	338.71%	-86.79%	40.44%	169.18%	281.13%
EPS Q/Q Growth	103.70%	-4,100.00%	172.50%	-65.52%	100.00%	0.00%	330.00%	-87.21%	45.45%	162.50%	283.33%
Operating Cash Flow Q/Q Growth	145.73%	-818.88%	244.84%	-65.95%	-13.98%	152.85%	-36.15%	-49.67%	214.70%	16.15%	-165.60%
Free Cash Flow Firm Q/Q Growth	-112.28%	-216.07%	83.69%	-386.00%	82.40%	430.14%	419.98%	-120.72%	49.68%	-103.91%	-625.39%
Invested Capital Q/Q Growth	171.34%	-20.38%	114.84%	5.79%	54.76%	-79.27%	-15.05%	731.03%	14.17%	8.68%	324.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.49%	93.09%	92.26%	88.85%	92.47%	92.47%	91.60%	91.65%	92.16%	92.23%	90.77%
EBITDA Margin	1.25%	-26.71%	15.06%	9.35%	12.99%	12.80%	60.05%	8.48%	12.99%	13.71%	7.13%
Operating Margin	1.84%	-27.29%	15.12%	7.39%	12.58%	12.64%	59.13%	7.90%	12.24%	12.83%	6.12%
EBIT Margin	1.09%	-26.58%	15.12%	7.53%	12.74%	12.87%	59.13%	8.14%	12.46%	13.05%	6.33%
Profit (Net Income) Margin	0.67%	-30.79%	19.82%	8.04%	13.80%	13.09%	55.37%	7.77%	10.08%	25.76%	96.33%
Tax Burden Percent	17.56%	124.99%	115.35%	78.83%	89.80%	84.43%	89.23%	68.35%	66.32%	160.96%	1,039.43%
Interest Burden Percent	353.76%	92.67%	113.62%	135.53%	120.63%	120.44%	104.94%	139.75%	121.97%	122.69%	146.32%
Effective Tax Rate	82.44%	0.00%	-15.35%	21.17%	10.20%	15.57%	10.77%	31.65%	33.68%	-60.96%	-939.43%
Return on Invested Capital (ROIC)	18.81%	-4,503.49%	1,369.36%	1,138.41%	259.30%	705.59%	2,246.75%	89.16%	108.30%	374.01%	302.81%
ROIC Less NNEP Spread (ROIC-NNEP)	18.66%	-4,497.17%	1,368.01%	1,137.31%	257.85%	704.27%	2,245.54%	88.11%	107.42%	371.94%	290.51%
Return on Net Nonoperating Assets (RNNOA)	-18.24%	4,466.57%	-1,337.59%	-1,126.01%	-235.93%	-683.20%	-2,158.79%	-79.47%	-95.17%	-343.16%	-223.75%
Return on Equity (ROE)	0.57%	-36.92%	31.78%	12.40%	23.38%	22.40%	87.95%	9.69%	13.13%	30.85%	79.06%
Cash Return on Invested Capital (CROIC)	-544.46%	-831.90%	-294.09%	-176.03%	-55.46%	782.22%	1,010.81%	259.13%	207.02%	238.57%	-60.08%
Operating Return on Assets (OROA)	0.95%	-27.20%	16.44%	8.11%	14.57%	14.86%	58.49%	8.16%	11.87%	11.84%	4.93%
Return on Assets (ROA)	0.59%	-31.50%	21.54%	8.67%	15.79%	15.11%	54.77%	7.79%	9.60%	23.38%	75.01%
Return on Common Equity (ROCE)	0.57%	-36.92%	31.78%	12.40%	23.38%	22.40%	87.95%	9.69%	13.13%	30.85%	79.06%
Return on Equity Simple (ROE_SIMPLE)	-28.00%	-41.09%	0.00%	-0.37%	5.92%	22.26%	0.00%	29.91%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	0.53	-40	40	12	27	27	137	13	21	58	181
NOPAT Margin	0.32%	-19.10%	17.45%	5.82%	11.30%	10.67%	52.76%	5.40%	8.11%	20.66%	63.65%
Net Nonoperating Expense Percent (NNEP)	0.14%	-6.32%	1.35%	1.10%	1.45%	1.33%	1.21%	1.05%	0.88%	2.06%	12.29%
Return On Investment Capital (ROIC_SIMPLE)	-	-	8.41%	-	-	-	17.68%	1.72%	2.48%	5.99%	14.26%
Cost of Revenue to Revenue	4.51%	6.91%	7.74%	11.15%	7.53%	7.53%	8.40%	8.35%	7.84%	7.77%	9.23%
SG&A Expenses to Revenue	58.08%	46.24%	48.25%	52.47%	48.38%	53.23%	50.11%	51.72%	50.46%	47.88%	54.80%
R&D to Revenue	35.57%	74.14%	28.89%	28.99%	31.51%	26.60%	38.80%	32.03%	29.46%	31.52%	29.85%
Operating Expenses to Revenue	93.65%	120.38%	77.13%	81.46%	79.89%	79.83%	32.47%	83.76%	79.93%	79.40%	84.64%
Earnings before Interest and Taxes (EBIT)	1.79	-56	35	15	31	32	154	20	33	36	18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2.07	-57	35	19	31	32	156	21	34	38	20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.84	9.42	11.91	6.54	5.20	4.42	4.17	3.62	4.39	3.93	3.68
Price to Tangible Book Value (P/TBV)	11.89	11.55	14.03	8.58	6.57	5.41	4.98	4.27	5.10	4.47	4.04
Price to Revenue (P/Rev)	7.07	5.40	7.08	3.73	3.01	2.75	3.19	2.78	3.54	3.44	4.22
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	87.84	19.85	13.48	12.10	16.25	13.79	11.56
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.14%	5.04%	7.42%	8.26%	6.15%	7.25%	8.65%
Enterprise Value to Invested Capital (EV/IC)	172.40	188.64	135.84	70.61	38.92	167.58	231.51	24.97	30.18	26.85	8.47
Enterprise Value to Revenue (EV/Rev)	6.39	4.85	6.53	3.21	2.50	2.14	2.43	2.10	2.83	2.66	3.48
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	76.90	16.90	9.82	8.76	11.95	11.26	32.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	89.03	17.50	10.10	8.89	12.17	11.57	34.82
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	4,959.10	145.98	18.82	11.51	10.29	14.68	12.12	12.65
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	284.02	40.94	27.63	9.80	14.78	14.02	15.34	14.01	33.98
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	18.07	10.25	13.37	18.24	20.20	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.11	0.11	0.09	0.00	0.06	0.00	0.05	0.05	0.03
Long-Term Debt to Equity	0.00	0.00	0.11	0.11	0.09	0.00	0.06	0.00	0.05	0.05	0.03
Financial Leverage	-0.98	-0.99	-0.98	-0.99	-0.92	-0.97	-0.96	-0.90	-0.89	-0.92	-0.77
Leverage Ratio	1.51	1.57	1.61	1.80	1.71	1.71	1.66	1.62	1.60	1.54	1.40
Compound Leverage Factor	5.35	1.45	1.83	2.44	2.06	2.06	1.75	2.26	1.95	1.89	2.05
Debt to Total Capital	0.00%	0.00%	9.97%	9.58%	8.37%	0.00%	5.43%	0.00%	5.14%	4.48%	3.20%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	9.97%	9.58%	8.37%	0.00%	5.43%	0.00%	5.14%	4.48%	3.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	90.03%	90.42%	91.63%	100.00%	94.57%	100.00%	94.86%	95.52%	96.80%
Debt to EBITDA	0.00	0.00	-0.68	-113.60	1.63	0.00	0.18	0.00	0.18	0.17	0.36
Net Debt to EBITDA	0.00	0.00	5.65	986.38	-15.88	0.00	-3.04	0.00	-3.01	-3.29	-6.93
Long-Term Debt to EBITDA	0.00	0.00	-0.68	-113.60	1.63	0.00	0.18	0.00	0.18	0.17	0.36
Debt to NOPAT	0.00	0.00	-0.93	93.51	3.10	0.00	0.21	0.00	0.23	0.19	0.14
Net Debt to NOPAT	0.00	0.00	7.73	-811.95	-30.14	0.00	-3.57	0.00	-3.70	-3.54	-2.67
Long-Term Debt to NOPAT	0.00	0.00	-0.93	93.51	3.10	0.00	0.21	0.00	0.23	0.19	0.14
Altman Z-Score	5.64	3.35	6.88	2.20	2.01	2.07	3.21	3.37	4.44	4.55	7.75
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.62	2.38	2.42	2.04	2.16	2.29	2.38	2.88	2.91	3.02	3.83
Quick Ratio	2.45	2.10	2.13	1.73	1.81	1.96	2.18	2.63	2.67	2.77	3.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-21	-68	-11	-54	-9.43	31	162	-34	-17	-34	-250
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,914.13%	0.00%	21,534.01%	19,146.39%	-1,216.75%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.88	1.02	1.09	1.08	1.14	1.15	0.99	1.00	0.95	0.91	0.78
Accounts Receivable Turnover	7.35	8.51	9.05	10.13	9.60	9.73	9.72	9.94	9.65	9.78	9.73
Inventory Turnover	1.76	1.97	1.96	1.85	1.83	1.91	2.83	1.87	1.68	1.88	3.14
Fixed Asset Turnover	90.25	110.92	136.64	163.33	190.75	209.48	217.02	253.25	264.96	272.12	182.76
Accounts Payable Turnover	0.89	2.34	2.75	3.42	3.81	4.97	4.85	4.24	4.09	4.14	6.57
Days Sales Outstanding (DSO)	49.63	42.90	40.31	36.02	38.03	37.51	37.54	36.72	37.83	37.31	37.50
Days Inventory Outstanding (DIO)	207.20	185.65	186.08	197.32	199.91	191.59	128.82	195.40	217.90	194.50	116.10
Days Payable Outstanding (DPO)	409.24	155.69	132.76	106.60	95.82	73.51	75.23	86.15	89.21	88.10	55.56
Cash Conversion Cycle (CCC)	-152.41	72.85	93.64	126.74	142.11	155.59	91.13	145.96	166.52	143.71	98.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	20	16	35	37	57	12	10	84	96	104	440
Invested Capital Turnover	58.26	235.73	78.49	195.44	22.96	66.13	42.58	16.52	13.35	18.11	4.76
Increase / (Decrease) in Invested Capital	22	27	51	66	37	-4.40	-25	47	38	92	430
Enterprise Value (EV)	3,519	3,066	4,744	2,609	2,225	1,986	2,331	2,089	2,883	2,787	3,732
Market Capitalization	3,895	3,412	5,140	3,036	2,685	2,551	3,053	2,770	3,610	3,600	4,519
Book Value per Share	$2.43	$2.21	$2.63	$2.82	$3.13	$3.48	$4.40	$4.59	$4.91	$5.44	$7.25
Tangible Book Value per Share	$2.01	$1.80	$2.23	$2.15	$2.47	$2.84	$3.68	$3.89	$4.23	$4.78	$6.61
Total Capital	396	362	480	513	564	577	775	765	867	960	1,268
Total Debt	0.00	0.00	48	49	47	0.00	42	0.00	45	43	41
Total Long-Term Debt	0.00	0.00	48	49	47	0.00	42	0.00	45	43	41
Net Debt	-375	-346	-397	-427	-460	-565	-723	-682	-727	-813	-787
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.45	0.00	0.30	0.39	4.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-71	-56	-83	-132	-116	-121	-221	-113	-141	-137	-43
Debt-free Net Working Capital (DFNWC)	305	290	362	345	391	444	543	568	631	720	785
Net Working Capital (NWC)	305	290	362	345	391	444	543	568	631	720	785
Net Nonoperating Expense (NNE)	-0.58	25	-5.49	-4.57	-6.06	-6.05	-6.77	-5.80	-5.20	-14	-93
Net Nonoperating Obligations (NNO)	-375	-346	-397	-427	-460	-565	-723	-682	-727	-813	-787
Total Depreciation and Amortization (D&A)	0.28	-0.27	-0.14	3.74	0.62	-0.18	2.40	0.84	1.40	1.85	2.25
Debt-free, Cash-free Net Working Capital to Revenue	-12.83%	-8.92%	-11.39%	-16.17%	-12.99%	-13.02%	-23.11%	-11.36%	-13.83%	-13.05%	-3.97%
Debt-free Net Working Capital to Revenue	55.31%	45.83%	49.81%	42.36%	43.91%	47.82%	56.74%	57.05%	61.88%	68.74%	73.26%
Net Working Capital to Revenue	55.31%	45.83%	49.81%	42.36%	43.91%	47.82%	56.74%	57.05%	61.88%	68.74%	73.26%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.01	($0.40)	$0.29	$0.10	$0.20	$0.20	$0.87	$0.11	$0.16	$0.43	$1.62
Adjusted Weighted Average Basic Shares Outstanding	163.46K	164.23M	163.82M	164.80M	165.55M	165.97M	165.72M	166.81M	167.83M	168.84M	168.36M
Adjusted Diluted Earnings per Share	$0.01	($0.40)	$0.29	$0.10	$0.20	$0.20	$0.86	$0.11	$0.16	$0.42	$1.61
Adjusted Weighted Average Diluted Shares Outstanding	165.05K	164.23M	163.82M	166.62M	166.17M	166.18M	166.36M	167.67M	168.68M	170.65M	169.92M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	163.73M	164.18M	164.77M	165.22M	165.88M	166.39M	166.79M	167.36M	168.71M	169.18M	170.49M
Normalized Net Operating Profit after Tax (NOPAT)	2.13	-40	24	12	27	27	137	13	21	25	12
Normalized NOPAT Margin	1.29%	-19.10%	10.59%	5.82%	11.30%	10.67%	52.76%	5.40%	8.11%	8.98%	4.29%
Pre Tax Income Margin	3.84%	-24.63%	17.18%	10.20%	15.37%	15.50%	62.05%	11.37%	15.20%	16.00%	9.27%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

ACADIA Pharmaceuticals (NASDAQ: ACAD) has delivered a multi-year revenue expansion with solid gross margins and a generally healthy balance sheet from 2022 through 2025. While quarterly profitability has fluctuated due to operating expenses and unusual items in some periods, the company has shown improving per‑share earnings and steady liquidity, supported by a cash balance in the low to mid hundreds of millions. The bullets below summarize the most important observed trends from the last four years of quarterly statements.

Strong revenue growth trend: operating revenue rose from about $136.5 million in 2022, Q4, to $283.99 million in 2025, Q4, indicating sustained top‑line growth over the period.
Gross margins remain very solid: total gross profit margins have hovered around 90% (e.g., 90%+ in multiple quarters), signaling efficient product economics even as expenses change.
Earnings per share progressed meaningfully: diluted EPS improved from around $0.86–$0.87 in 2024 to about $1.61–$1.62 in 2025, reflecting stronger profitability per share over time.
Operating cash flow improved in mid‑2025: net cash from continuing operating activities was positive in Q2 and Q3 2025 (roughly $64M and $74M), supporting liquidity for ongoing initiatives; despite a dip in Q4 2025, the trend across 2025 was supportive of liquidity.
Robust near‑term liquidity: cash and equivalents were in the mid‑$200Ms across 2024–2025 quarters (e.g., about $254–$258M in recent quarters), providing a cushion to fund R&D and other activities without immediate external financing.
R&D intensity remains high and relatively stable: quarterly RD expenses were substantial (e.g., Q4 2025 RD expense around $84.8M vs. $100.7M in Q4 2024), indicating ongoing investment in the development pipeline that can support future growth but also press margins in the near term.
SG&A remains a meaningful, rising cost component: selling, general, and administrative expenses increased in some periods (e.g., Q4 2025 SG&A around $155.6M vs. $130.1M in Q4 2024), contributing to higher operating expenses and variable operating income.
Conservative debt picture with lease liabilities: the company shows capital lease obligations and other liabilities, but no large long‑term debt, suggesting a relatively cautious balance sheet structure and manageable fixed obligations.
One‑off items can skew quarterly profitability: Q4 2025 net income included a sizable tax benefit that materially boosted net income, so investors should consider adjusting for this item when assessing ongoing profitability.

Notes for investors: While ACADIA’s quarterly net income and operating income can swing due to working capital, tax items, and R&D/SG&A timing, the four‑year trend points to growing revenue, high gross margins, and improving per‑share profitability. The balance sheet remains solid with ample liquidity and limited debt, though continued emphasis on RD investment and potential working capital shifts could impact near‑term cash flow. As always, it’s helpful to compare these quarterly results to ongoing timelines for product development milestones and external financing needs.

05/06/26 04:32 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About ACADIA Pharmaceuticals' Financials

When does ACADIA Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, ACADIA Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has ACADIA Pharmaceuticals' net income changed over the last 10 years?

ACADIA Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $391 million in 2025, falling from -$164.44 million in 2015. The previous period was $226.45 million in 2024. Check out ACADIA Pharmaceuticals' forecast to explore projected trends and price targets.

What is ACADIA Pharmaceuticals' operating income?

ACADIA Pharmaceuticals' total operating income in 2025 was $104.81 million, based on the following breakdown:

Total Gross Profit: $982.51 million
Total Operating Expenses: $877.70 million

How has ACADIA Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, ACADIA Pharmaceuticals' total revenue changed from $61 thousand in 2015 to $1.07 billion in 2025, a change of 1,756,465.6%.

How much debt does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals' total liabilities were at $336.81 million at the end of 2025, a 26.0% decrease from 2024, and a 1,421.7% increase since 2015.

How much cash does ACADIA Pharmaceuticals have?

In the past 10 years, ACADIA Pharmaceuticals' cash and equivalents has ranged from $69.42 million in 2017 to $326.03 million in 2020, and is currently $177.70 million as of their latest financial filing in 2025.

How has ACADIA Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, ACADIA Pharmaceuticals' book value per share changed from 1.98 in 2015 to 7.25 in 2025, a change of 266.5%.

Related Companies

Financial statements for NASDAQ:ACAD last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About ACADIA Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Financials

Annual Income Statements for ACADIA Pharmaceuticals

Quarterly Income Statements for ACADIA Pharmaceuticals

Annual Cash Flow Statements for ACADIA Pharmaceuticals

Quarterly Cash Flow Statements for ACADIA Pharmaceuticals

Annual Balance Sheets for ACADIA Pharmaceuticals

Quarterly Balance Sheets for ACADIA Pharmaceuticals

Annual Metrics And Ratios for ACADIA Pharmaceuticals

Quarterly Metrics And Ratios for ACADIA Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About ACADIA Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools